medcelerator · clinician one-pager

First FDA-Approved Implant Treatment for MacTel Eye Disease

Encelto (revakinagene taroretcel-lwey) — encapsulated cell implant for macular telangiectasia type 2

FDA Approved · United States · September 21, 2026

Condition: Macular Telangiectasia Type 2

Who this is for

This is for adults living with idiopathic macular telangiectasia type 2 — and the caregivers who help them — who may be candidates for labelled US Encelto encapsulated cell implants at a vitreoretinal surgery centre after imaging confirms MacTel. It explains the first FDA-approved MacTel therapy, the twin Phase 3 EZ-loss results, surgical and vision-loss honesty, ENCELTOconnect navigation, and why authorised is not funded — without treating completed pivotal research as walk-in enrolment, treating an incomplete centre list as permanent, or importing a US implant. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/encelto-revakinagene-taroretcel